Aurobindo lays out plans for 3 new plants

India's Aurobindo Pharma intends to beef up its manufacturing capacity over the next three years. According to LiveMint, it will build three new plants, the costs of which will be included in its 900 crore rupee ($137 million) capital outlay plan for the next year. The publication said the plans include an oral solid finished dosages facility at Naidupeta, an oral finished dosage facility in Visakhapatnam, and a semisynthetic penicillin plant at Jadcherla, near Hyderabad. Report

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.